Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®]

Author： Duggan Sean T.  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.70, Iss.15, 2010-10, pp. : 1973-1986

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®]†: Profile Report

By Duggan Sean T.  

Pediatric Drugs, Vol. 14, Iss. 1, 2012-02 ,pp. : 67-69

Adis International

Access to resources Recommend Favorite

Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed): In Older Adults

By Sanford Mark  

Drugs, Vol. 72, Iss. 9, 2012-06 ,pp. : 1243-1255

Adis International

Access to resources Recommend Favorite

Immunogenicity of pneumococcal 13-valent conjugate vaccine

By  

Inpharma, Vol. 1, Iss. 1591, 2007-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

South Africa plans to phase in routine vaccination with pneumococcal 7-valent CRM197 vaccine conjugate [Prevenar]

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 563, 2008-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

The safety of 7-valent pneumococcal conjugate vaccine

By Ghaffar Faryal  

Expert Opinion on Drug Safety, Vol. 4, Iss. 4, 2005-07 ,pp. : 631-636

Informa Healthcare

Access to resources Recommend Favorite